Auriga Maintains Buy on Thermo Fisher Scientific

Auriga is out with its report today on Thermo Fisher Scientific TMO, maintaining Buy, after announcing the close of its Phadia acquisition. In its report, Auriga writes, "Overall, Phadia looks like another solid asset and should benefit from TMO's established global distribution channels. We are increasing our 2011 and 2012 estimates to reflect Phadia, offset by higher interest expenses related to transaction financing. We reiterate our Buy rating and $73 price target." Shares of TMO closed Tuesday at $52.16.